

Revised Agenda MedTech Task Force

The Corporation of the City of Brampton

Date: Thursday, November 7, 2024

Time: 4:00 p.m.

Location: Hybrid Meeting - Virtual Option & In-Person in Council Chambers – 4th Floor –

City Hall

Members: Deputy Mayor H. Singh (Chair)

Dr. Mohamed Lachemi, President, Toronto Metropolitan University (Vice-Chair)

Regional Councillor M. Palleschi - Wards 2 and 6 Regional Councillor R. Santos - Wards 1 and 5 Regional Councillor G. Toor - Wards 9 and 10

Tony Chahine, CEO, Myant Inc.

Vito Ciciretto, President and CEO, Dynacare

Jason Field, President and CEO, Life Sciences Ontario Anton Katipunan, Development with RioCan, RioCan

Brian Leahy, Director, External Community Relations, Algoma University Dr. Frank Martino, President & CEO, William Osler Health Systems

Jailpaul Massey-Singh, CEO, Brampton Board of Trade

David Moores, Vice president, Development Engineering, Orlando Corporation

Dr. Dante Morra, Chief of Medical Staff, Trillium Health Partners Dr. Janet Morrison, President & Vice Chancellor, Sheridan College

Peter Nikolakakos, Executive Vice President, Development & Planning, First

Gulf

John Sincerbox, Medtronic Canada

Carl Rodrigues, CEO, SOTI

Ken Spears, General Manager / Vice-President, Boston Scientific Canada

Darren Steedman, Vice-President, DG Group Jay Stevens, CEO, The Stevens Company

Amy Swanson, Vice-President, MedTech Canada

Andreas Wegner, General Manager, Taro Pharmaceuticals

Mahes Wickramasinghe, EVP & Chief Administrative Officer, Rogers Vincci Wilson, VP Development, NorthWest Healthcare Properties REIT

Blair Wolk, President, Orlando Corporation

David Wyatt, Senior Vice President, Morguard Investments Ltd

For inquiries about this agenda, or to make arrangements for accessibility accommodations for persons attending (some advance notice may be required), please contact: Tammi Jackson, Legislative Coordinator, Telephone 905.874.3829, TTY 905.874.2130 cityclerksoffice@brampton.ca

Note: Meeting information is also available in alternate formats upon request.

1. Call to Order

2. Approval of Agenda

3. Declarations of Interest under the Municipal Conflict of Interest Act

4. Previous Minutes

The minutes were considered by Committee of Council on June 26, 2024, and were approved by Council on July 10, 2024. The minutes are provided for Committee's information.

5. Presentations / Delegations

- 5.1 Opening Remarks by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU).
- *5.2 Presentations by Stakeholders:
 - 1. William Osler Health System
 - Dr. Greg Rutledge, Chief of Staff and Executive VP, Medical & Academic Affairs
 - Tiziana Rivera, Executive VP, Quality and Research and Chief Nursing Executive
 - 2. Ontario Centre of Innovation
 - Jeff Van Heumen, Assistant Vice-President, Business Development

The presentations were received and published on the City's website on November 5, 2024.

To be received.

6. Other / New Business / Information Items

- 6.1 Follow-up on Key Projects:
 - 1. Wet Labs Feasibility Study / Consultation Update

 Daniel Lacey, AVP, CBRE Life Sciences; Ross Wallace, Principal, Santis Health

To be received.

6.2 MedTech Task Force - 2025 Meeting Schedule

To be received.

- 7. Member Questions / Roundtable
- 8. Correspondence
- 9. Question Period
- 10. Public Question Period

15 Minute Limit (regarding any decision made at this meeting)

11. Adjournment

Closing Remarks by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU).

Next Scheduled Meeting: Thursday, April 24, 2025, at 4:00 p.m. in the Council Chambers at Brampton City Hall.

Note: Refreshments and networking for Task Force members and invited guests will be held in the Council Lounge following the meeting.



Minutes

MedTech Task Force

The Corporation of the City of Brampton

Thursday, May 30, 2024

Members Present: Deputy Mayor H. Singh (Chair)

Dr. Mohamed Lachemi, President, Toronto Metropolitan

University (Vice-Chair)

Regional Councillor R. Santos - Wards 1 and 5

Dave Casimiro, Managing Director, NorthWest Healthcare

Properties REIT

Vito Ciciretto, President and CEO, Dynacare Sheri Dodd, President, Medtronic Canada

Jason Field, President and CEO, Life Sciences Ontario Jaipaul Massey-Singh, CEO, Brampton Board of Trade Dr. Frank Martino, President & CEO, William Osler Health

Systems

Dr. Janet Morrison, President & Vice Chancellor, Sheridan

College

Jay Stevens, CEO, The Stevens Company

Amy Swanson, Vice-President, MedTech Canada

Andreas Wegner, General Manager, Taro Pharmaceuticals Vincci Wilson, VP NorthWest Healthcare Properties REIT Mahes Wickramasinghe, EVP & Chief Administrative Officer,

Rogers

David Wyatt, Senior Vice President, Morguard Investments Ltd Deepak Sharma, William Osler Health Systems (Alternate)

Members Absent: Regional Councillor M. Palleschi - Wards 2 and 6

Regional Councillor G. Toor - Wards 9 and 10

Tony Chahine, CEO, Myant Inc.

Anton Katipunan, Development with RioCan, RioCan

Brian Leahy, Director, External Community Relations, Algoma

University

David Moores, Vice President, Development Engineering,

Orlando Corporation

Dr. Dante Morra, Chief of Medical Staff, Trillium Health Partners Peter Nikolakakos, Executive Vice President, Development & Planning, First Gulf Carl Rodrigues, CEO, SOTI Ken Spears, General Manager / Vice-President, Boston Scientific Canada Darren Steedman, Vice-President, DG Group Blair Wolk, President, Orlando Corporation

1. Call to Order

The meeting was called to order at 4:08 p.m. and adjourned at 5:39 p.m.

2. Approval of Agenda

The following motion was considered.

MTTF001-2024

That the agenda for the MedTech Task Force Committee Meeting of May 30, 2024, be approved as published and circulated.

Carried

3. <u>Declarations of Interest under the Municipal Conflict of Interest Act</u>

Nil

4. <u>Previous Minutes</u>

The minutes were considered by Committee of Council on November 29, 2023, and were approved by Council on December 6, 2023. The minutes were provided for Committee's information.

5. Presentations / Delegations

5.1 Presentation by Stakeholders:

- 1. Algoma University
- o Dr. Istvan Imre
- 2. Roga Life
- o Dr. Alison Smith, Co-Founder and Chief Scientist
- 3. Medical Alley, MN
- Frank Jaskulke

Dr. Istvan Imre, Algoma University, provided a brief overview of the company that included the following:

- Two initiatives being implemented:
 - Ontario Mental Health & Addictions Research Training Institute
 (OMHARTI) at the Sault Ste. Marie and Brampton locations
 - National Centre of Excellence in Immersive Technology partnering with Unity.
- Outlined the purpose and goals of OMHARTI.
 - Brampton location 145 Queen Street East newly leased independent building.
 - The facility will host undergraduate and graduate programming in the areas of Psychology and Social Work.
- The National Centre of Excellence (CoE) in Immersive Technology focuses on bridging the divide between the augmented reality.
 - Outlined the vision and mission of the initiative.
 - CoE Pillars Education Advancement and Skill Development;
 Innovation and Industry collaboration; Community Integration and Outreach.

Dr. Alison Smith, Co-Founder and Chief Scientist, Roga Life, provided a brief overview of the company that included the following:

- Roga Life is an early stage MedTech startup that is part of the Brampton Venture Zone.
- Mental healthcare platform to treat employee stress, anxiety and burnout.
- Sells corporate health benefits.
- Since the pandemic stress and anxiety have significantly increased, especially for those within the workforce.
 - 72 percent of employees are experiencing intense stress resulting in performance decline, absenteeism, turnover and medical expenses.
 - To deal with such anxieties people only have access to talk therapists and medication.
 - Looking for MedTech solutions to assist individuals wherever they are.

- Mental Healthcare Platform wearable device (effectively reduces stress and burnout) and AI guided meditations (personalized guided meditations and treatment progress analytics).
- Currently on the market as a "wellness device" for intense stress and burnout.
- Future goal is to achieve "Medical Device Status" to treat anxiety.

Frank Jaskulke, Medical Alley, MN, provided a brief overview of the company that included the following:

- Not-for-profit trade association.
- Outlined the company's mission and vision.
- Partnership services: connections, advocacy, insights, engagement.
- Foundational and sustaining partners.
- Medical Alley Board of Directors
- Strategic Value Creation four core initiatives: Medical Alley Starts,
 Medical Alley Global, Healthcare Transformation Initiative (HTI) and Local and Federal Policy.
- Strategic Initiatives: enabling healthcare innovation, elevate business progress, transform health equity.

The following motion was considered.

MTTF002-2024

That the following presentations to the MedTech Task Force Committee Meeting of May 30, 2024, re:

- 1. Algoma University
- 2. Roga Life
- 3. Medical Alley, MN

be received.

Carried

6. Other / New Business / Information Items

The following motion was considered.

6.1 Updates:

- 1. The Brampton Medical School
- Dr. Mohamed Lachemi
- 2. Update from the Brampton Venture Zone
- John MacRitchie and Fardan Khan

Dr. Mohamed Lachemi, President, Toronto Metropolitan University (TMU), provided an update on the Brampton Medical School that included:

- On track to welcome the first group of medical learners in 2025:
 - 105 residents (July 2025 Intake)
 - 94 MD students (September 2025 Intake)
- Clinical affiliations will ensure the delivery of high-quality placements and celebrate primary care.
- Integrated Health Centre (IHC) will increase primary care access.
- Accreditation process is proceeding on schedule.

John MacRitchie and Fardan Khan, Brampton Venture Zone, provided a brief update on the Brampton Venture Zone that included the work undertaken to date and the work that is upcoming for 2025.

The following motion was considered.

MTTF003-2024

That the following updates to the MedTech Task Force Committee Meeting of May 30, 2024, re:

- 1. Brampton Medical School
- 2. Brampton Venture Zone

be received.

Carried

6.2 Follow-up on Key Projects:

- 1. Wet Labs Outline of Feasibility Study / Consultation
- Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton
- 2. The MedTech Conference, Toronto October 15 17, 2024
- Amy Swanson
- Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton
- 3. Other Items Sector MedTech Outline (new) with Our Stakeholders (Including BIO 2024)
- Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton

Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the Wet Lab - Feasibility Study/Consultation.

Amy Swanson, Vice-President, MedTech Canada and Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the subject matter that included the following:

- Four pillars of the conference: Networking, education program, partnering and investor forum and the MedTech campus.
- Flexpass Campaign
- Registration rates.
- All-access pass includes: four days of education, networking, access to the Medtech campus, and partnering with thousands of Medtech innovators.
- Partnered with Destination Toronto at the conference and will be at booth 700.
- Deputy Mayor Singh and Councillor Toor will be available on October 17th for half a day.
- Looking at setting up a panel discussion at the booth.

Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the subject matter that included the following:

- Looking to update the marketing panel.
- Change the narrative and look at our research, startup companies.
- Asking for input or key items to showcase moving forward into 2025.

The following motion was considered.

MTTF004-2024

That the following Verbal Updates on Key Projects to the MedTech Task Force Committee Meeting of May 30, 2024, re:

- 1. Wet Labs Outline of Feasibility Study/Consultation
- 2. MedTech Conference, Toronto October 15 17, 2024
- 3. Sector MedTech Outline (new) with Our Stakeholders (Including BIO 2024).

be received.

Carried

6.3 Information Item re: Concept for a 2025 Conference in Brampton –Brain Injury Association Peel Halton, Nick Kuryluk and Sarah Diaz

Nick Kuryluk and Sarah Diaz, Brain Injury Association Peel Halton provided information regarding the Concept for a 2025 Conference in Brampton and advised they were seeking the Committee's support and financial backing to secure the Rose Theatre for a one-and-a half to two-day conference in 2025.

The following motion was considered.

MTTF005-2024

That the presentation from Sarah Diaz, Brain Injury Association, Peel Halton, re: Concept for a 2025 Conference in Brampton, to the MedTech Task Force Committee Meeting of May 30, 2024, be received.

Carried

7.	Member Questions / Roundtable Nil		
8.	<u>Correspondence</u> Nil		
9.	Question Period Nil		
10.	Public Question Period Nil		
11.	Adjournment Closing Remarks were provided by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU). The following motion was considered. MTTF006-2024 That the MedTech Task Force do now adjourn to meet again for a Regular Meeting of Committee on Thursday, November 7, 2024 at 4:00 p.m. or at the call of the Chair. Carried		
		Deputy Mayor H. Singh (Chair)	
	N	Mohamed Lachemi (Vice-Chair)	









William Osler Health System Osler Research Institute for Health Innovation

MedTech Task Force

November 7, 2024

Dr. Greg Rutledge, Chief of Staff and Executive Vice President, Medical & Academic Affairs

Tiziana Rivera, Executive Vice President of Quality, Research and Chief Nursing Executive











Dr. Greg Rutledge

- Chief of Staff and Executive Vice President, Medical and Academic Affairs
- Regional Lead of Emergency Medicine at Ontario Health West
- Former Emergency Medicine
 Program Director at McMaster
 University and Chief of
 Emergency Medicine at St.
 Joseph's Healthcare in
 Hamilton
- Medical Director for the Toronto Marlies and Emergency Physician for the Toronto Maple Leafs



Tiziana Rivera

- Executive Vice President, Quality, Research and Chief Nursing Executive
- Adjunct Professor, Daphne Cockwell School of Nursing, Toronto Metropolitan University
- Award of Excellence in Nursing Leadership recipient from Ontario Hospital Association
- Supporting international adoption of best practices with the Registered Nurses' Association of Ontario
- Surveyor, Accreditation Canada

Growing Community, Growing Needs

1.3M+ residents


Fast-growing, high-density population

At least 63% visible minorities

Seniors population will double over the next 20 years

Greater proportion of medicallycomplex patients

One of the highest rates of diabetes in Ontario





Page 20 of 76













Osler's Sites



Brampton Civic Hospital



Etobicoke General Hospital



Peel Memorial Centre for Integrated Health and Wellness





Reactivation Care Unit



Page 21 of Withdrawal Management Centre



Osler By the Numbers 2023-24



1,151,329 **Patient Visits**



300,962

Emergency and Urgent Care Visits



560,777

Outpatient Clinic Visits



52,592

Inpatients



7,953 **Births**



4,604

Cancer Surgeries



577,871

Diagnostic Images



72,108

Surgeries



7,154 Staff

1,108

Physicians



1,572

Learners

Page 22 of 76



1,100

Volunteers

Osler is one of the **busiest** community hospitals in Canada



for our people and communities

OSLER'S VISION

World-class health care inspired by our people and communities

OSLER'S MISSION

Innovative health care delivered with compassion

OSLER'S VALUES

- O Respect
- Excellence
- Service
- O Compassion
- Innovation
- Collaboration

OSLER'S PROMISE

Going beyond



< Scan to learn more



Strategic Directions

People & Culture

Inspiring a sense of belonging that supports people to be their best and do their best



Strategic Foundations



Equity, Diversity & Include 23 of 76



Innovation & Collaboration



Infrastructure & Technology




Financial Stewardship



System Leadership and Firsts

- Endovascular Therapeutics Suite
- Cardiology Program including ICD implantation
- Multiple advanced surgical techniques
 - Robot-assisted knee replacement
 - Intellijoint HIP
 - MOLLI 2 System
- Repetitive Transcranial Magnetic Stimulation
- Hospital-based Paediatric Diabetes Education Centre
- Butterfly Approach to Dementia Care
- Cancer care
 - Most oncology clinical trials of any community hospital
 - Designated Centre of Integrated Oncology and Palliative Care
 - Next Generation Sequencing
 - In-house liquid biopsy for cancer testing








Innovation in Action


Conference Report


Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada

Stephanie Snow ¹, Christine Brezden-Masley ², Michael D. Carter ³, Neesha Dhani ⁴, Cassandra Macaulay ⁵, Ravi Ramjeesingh ¹, Michael J. Raphael ⁶, Monika Slovinec D'Angelo ⁵ and Filomena Servidio-Italiano ^{5,*}

Point of Care Liquid Biopsy in Cancer Care









Medical Education at Osler

- As a community teaching hospital, Osler is a site of learning for medical students, residents and fellows enrolled in a Canadian medical school
- A unique three school affiliation model: Toronto Metropolitan University, McMaster, University of Toronto
- Success elements include: engaged staff, tremendous clinical teaching opportunities, diverse patient and provider populations
- Exponential (9x) rise in medical trainee days anticipated over next five years






Medical Education Ecosystem and Innovation

- Talent pipeline for local healthcare and life sciences
- Recruitment of academic physicians, clinician-scientists into Brampton, supported by medical learners
- Enhanced platform for community partnerships, research and industry collaborations
- Deepen the culture of inquiry
- Presence of more medical learners will enhance Brampton's reputation as a life sciences hub and foster synergies with University innovation centres



Osler Research Institute for Health Innovation (ORIHI) Strategy-At-A-Glance






ORIHI By The Numbers



FY2023-2024	OVER THE LAST DECADE		
76 Clinical Trials	591 Publications		
1,150 Subjects Enrolled In Studies	252 Conference Abstracts		
34 Full Time Staff	> 50 Programs Areas Conducted Research		
TOP 5 RESEARCH PROGRAMS 1. Oncology 2. Infectious Disease	537 Studies		
3. Cardiology4. Hepatology5. Ophthalmology6. Pediatrics	259 Individuals have lead research projects		

How Can ORIHI Contribute to the Innovation Ecosystem?

Partnership Pathway



Page 30 of 76

Requirements & Considerations

Requirements for device or drug studies at ORIHI as laid out in Health Canada Division 5 Regulations.

Minimum requirements are as follows:

- Device Investigational Testing Authorization (ITA) from Health Canada
- **Drug** No Objection Letter (NOL) from Health Canada

Requirements of Study Teams:

- Require an Osler staff or physician to be a Principal Investigator
- Require all study staff to have their TCPS2, GCP and Health Canada Division 5 certifications

Types of Studies ORIHI conducts:

- Clinical Trials Phase 2,3,4 (No Phase 1, pre-clinical studies or animal studies at this time)
- Al/machine learning studies
- Qualitative Studies

Page 31 of 76

ORIHI Service Offerings

Pay-for-Use

- Research Study Staff
 - Protocol development and consent forms
 - Recruitment and participant consent
 - Data collection
 - Study specific assessments
 - Coordinate clinical research
 - Timelines and budgets

- Research Ethics Board
 - Pre-Consultation
 - Application
 - Delegated and Full Board Review
- Laboratory and Diagnostic Services

Additional offerings at no charge

- Identifying an Osler Principal Investigator
- Consultation or working with ORIHI Community-Based Research Advisory Committee access to community voices and perspectives

15

Celebrate Research Week – November 18-22

Milestone Moments

Official launch of Osler Research Institute for Health Innovation (ORIHI)

Release of ORIHI Strategic Plan 2025-2030

City-wide proclamation of Celebrate Research Week

Full Agenda:



ORIHI Banner Reveals across Osler's sites



Keynote: Dr. Parneet Cheema, Head of Cancer Research, Osler

Panel: Health Systems Transformation at City Hall Conservatory

Unique Moments

Art/Science Exhibit:
Daniela Brill Estrada's
"Our Celestial Bodies" and
local Brampton artists



Keynote: Equitable
Healthcare for Diverse
Communities

Community Research Fair and Networking Event at City Hall Conservatory

TMU Immersive
Experience of the
School of Medicine



Panel: How Technology is Advancing Health Research

Celebrate Research Week Schedule

Date	November 18	November 19	November 20	November 21	November 22
Theme	Celebration Day	Partnership Day	Health Systems Transformation Day	Innovation and Technology Day	Community Health, Wellbeing & Education Day
Location	Brampton Civic Hospital	Etobicoke General Hospital	Peel Memorial Centre for Integrated Health and Wellness	Brampton Civic Hospital	Brampton Civic Hospital
ORIHI Banner Reveal	10:00 a.m.	2:00 p.m.	10:00 a.m.		
Keynote speaker and panels	10:45 a.m. Dr Parneet Cheema Head of Cancer Research	2:30 p.m. Dr Sergio Borgi Infectious Disease Specialist	10:30 a.m. Panel: Dr. Martin Chasen, Dr. Marco Iafolla, Tiziana Rivera moderated by Rishika Thakur, Central West Ontario Health Team	10:00 a.m. Panel Discussion moderated by Dr. Hina Marsonia, Pharmacist 2:00 p.m. Panel Discussion hosted by Brampton Venture Zone and Altitude Accelerator	10:00 a.m. Keynote: Leah Stephenson, All.CAN Strategic Lead 12:00 p.m. Dr. Teresa Chan, Dean, Toronto Metropolitan University School of Medicine
Research Open House	12:00-1:30 p.m.	12:00-1:30 p.m.	12:00-1:30 p.m.		
Community		Community Research F ச் áge	Panel "Health Systems 34 of 76 ansformation" @ City Hall		





Ontario Centre of Innovation Leading in Life Science

Brampton Medtech Task Force Nov. 7, 2024

Jeff van Heumen AVP-Business Development

Page 36 of 76

What We Do



- ACCELERATE the development, commercialization, and adoption of Made-in-Ontario technologies to drive job creation and economic growth
- **CONNECT** industry, academic, and government to co-invest in collaborative R&D, technology development, and commercialization
- **DE-RISK** innovation, helping to attract customers and investors to companies
- Funded by the Ministry of Economic Development, Job Creation and Trade









RETURN ON INNOVATION

623

5,542

\$362M

Ontario Companies
Supported

Jobs (Created & Retained)

Incremental
Sales Revenue

\$734M

48,603

Follow-on private sector investment

Students engaged through workforce development in 14 Ontario regions

Supporting High-Potential Projects Across Ontario



Woodstock York



Ajax	Burlington	Fort William First Nation	
Alfred	Caledon	Georgetown	
Alvinston	Cambellford	Golden Lake	
mherstburg	Cambridge	Grand Bend	
Ancaster	Chatham		ı
Annan	Cobourg	Guelph	
Arnprior	Collingwood	Haliburton	
Arthur	Concord	Hamilton	
Aurora	Cornwall	Hanmer	
Aylmer	Crediton	Hannon	
Barrie	Dobbinton	Hanover	
Barry's Bay	Dorchester	Hearst	
Beamsville	Downsview	Huron-Kinloss	
Belleville	Drayton	Ilderton	
g Trout Lake	Dryden	Kanata	·
oomingdale	Dundas	Kawartha Lakes	N
Bolton	Dunnville	Kemptville	
	Dunrobin	Kenilworth	
owmanvillle		Kinburn	
racebridge	East Gwillimbury	Kingston	
Brampton	Eden	Kingsville	N
Brantford	Elmvale	Kitchener	ı
Breslau	Espanola	Kleinburg	
ruce Mines	Etobicoke	Kieliibuig	Ni

Lakeshore	Lake	Port Robinson	Tavistock
Langton	Nobleton	Port Severn	Tecumseh
LaSalle	North Bay	Prescott	Terrace Bay
Lindsay	North York	Prince Albert	Thedford
Lion's Head	Norwich	Puslinch	Thornhill
Listowel	Oakville	Quinte West	Thorold
Lively	Oldcastle	Richmond Hill	Thunder Bay
London	Orillia	Ridgetown	Tillsonburg
Maidstone	Orleans	Rosslyn	Timmins
Manotick	Oro Medonte	Saint-Laurent	Toronto
Maple	Oshawa	Sarnia	Trenton
Markham	Ottawa	Sault Ste. Marie	Uxbridge
Milton	Owen Sound	Scarborough	Vars
Mississauga	Paris	Shuniah	Vaughan
Mitchell	Parry Sound	Simcoe	Wallaceburg
Mount Hope	Penetanguishene	Smooth Rock Falls	Waterdown
Napanee	Peterborough	St. Catharines	Waterloo
Naughton	Pickering	St. Thomas	Welland
Nepean	Picton	Stittsville	Wellington
New Hamburg	Piscataway	Stoney Creek	Weston
Newmarket	Township	Stratford	Whitby
Niagara	Port Colborne	Strathroy	Windsor
Niagara-on-the-	Port Perry	Sudbury	Woodbridge

Page 39 of 76

OCI Programs & Funds



ACCELERATING TIME TO MARKET FOR MADE-IN-ONTARIO TECHNOLOGIES						
Technology Development Commercialization		Adoption				
Collaborate 2 Commercialize Program (C2C)		Digitalization Competence Centre (DCC)				
Life Sciences Innovation Funds (LSIF)		Innovating Digital Health Solutions (IDHS)				
Ready 4 Market Co-Investment Fund (R4M)						
Ontario Vehicle Innovation Network (OVIN)						
NEW	Critical Industrial Technolo	ogies (CIT)				





Life Sciences & Health Portfolio of Programs and Companies





Life Sciences Innovation Fund & Ready 4 Market Co-Investment Fund

OCI Investment Portfolio

Life Sciences Innovation Fund (LSIF)





- Ontario's leading Life Sciences and Healthcare Technologies fund
- Co-invests with angel investors in earlystage tech start-ups to support growth

Criteria

- Medical devices, therapeutics, and health IT
- Up to \$500k investments
- Have not raised more than \$3 million in third party investments
- Company must be Ontario based with a minimum of 1 Ontario investor





Life Sciences Innovation Fund (LSIF)



- Portfolio companies to date
 - Investment announcement































MOU Partners



 As part of the Life Sciences Innovation Fund, OCI has established MOUs with key organizations in the life sciences ecosystem in Ontario





















Ready 4 Market





- Ontario's leading pre-seed tech fund investing in all sectors
- Co-Investment Fund invests directly in academic affiliated companies to support early-stage commercialization and growth

• Criteria

- Less than 5 years since incorporation
- Raised less than \$1 million from 3rd party investors – must include 1 Ontario investor
- Up to \$250k investment





Ready 4 Market (R4M) - health tech companies



- Supports early-stage Ontario-based entrepreneurs in diverse sectors. Here are the portfolio companies in the health tech space that were invested prior to the creation of LSIF
 - 45 investments made







































Collaborate 2 Commercialize

Industry-Academia Collaborations

Collaborate 2 Commercialize (C2C)






- Supports technology development collaborations between industry and post-secondary institutions
 - Standalone Funding
 - NSERC Alliance

• Criteria

- Ontario-based for-profit companies
- Minimum of 2 years in Business with 5 or more FTEs
- Principal Investigator must be eligible to hold Tri-Council Funds





Project Examples – Biotechnology





Project Partners:

- Elarex Biotech; next-gen vaccine platform tech
- McMaster University

Project Description:

Viral vector vaccines using Adenovirus have recently been approved for use on humans. This project seeks to demonstrate that a transgene design works to create an exosome in situ that would contain a target antigen and adjuvant.

This vaccine would be orally administered and would act on the gut mucosal tissue. It is also the aim of this project to make this vaccine dose ultra-stable at room temperature.

Other Life Sciences Companies



Biotech:

- Arthritis Innovation Corporation
- Triumvira Immunologics
- PharmAla Biotech Inc
- Mannin Research

MedTech/Digital Health:

- Marion Surgical
- COSM Medical
- CloudDX

Other Project Samples (videos, sector agnostic)

- Avicanna & UHN: https://youtu.be/EkYE9UOsa2E?si=xhHDHh3UDOqkOlRX
- Evercloak & Lambton College: https://youtu.be/oCVn2AcUjP4?si=rMg0KzhAxXYT8pFG
- Beaver Rock & Georgian College: https://youtu.be/fHh3WXZulf4?si=4hVVUCkiQfiYOVDA
 Page 51 of 76



Innovating Digital Health Solutions

Adoption of Digital Health Solution

Innovating Digital Health Solutions (IDHS)



Background and overview

- IDHS enables Ontario Health Teams (OHTs) to collaborate with Ontario-based technology vendors in the evaluation, adoption, and implementation of digital health technologies. <u>Official announcement</u>.
- Launched in the Summer of 2023, the program deployed close to \$8M in 13 projects
- Collaboration between applicant (i.e. OHTs), technology partner (i.e. Ontario-based digital health technology business), and other partners (e.g., community-based organizations)
- OCI funding contribution: up to 50% to a maximum project cost of \$500K

Innovating Digital Health Solutions (IDHS)



Complete list of companies and health teams engaged

Health Teams

University Health Network
William Osler Health System
The Mississauga OHT
Kingston Health Sciences Centre
Bightshores Health System
North York General Hospital
Ottawa Heart Institute
Nothern York South Simcoe OHT
Durham OHT and Urgent Care Collaborative
Queens Square Family Health Team
Thunder Bay Regional Health Sciences Centre
Grand Bend Area Community Health Centre

Technology partners

Hero Al

Swift Medical

Caredove

OPTT

Hypercare

MyJourney

Badal.io

ESRI Canada

Greenspace Mental Health

Health Espresso

Chime Technology

Aurora Constellations

Continicare



Critical Industrial Technologies

Advancement and Adoption of Critical Technologies across Key Sectors

Critical Industrial Technologies - Advanced Manuf.



Background and overview

- CIT supports the implementation of critical technologies (i.e., 5G, AI, Cyber Security, Quantum, and Robotics) to propel four key sectors, including advanced manufacturing (AM). Official announcement of the \$50M to be deployed by the program.
- Ontario SMEs producing medical devices taking advantage of AM processes and implementing any of the critical technologies in their manufacturing could be eligible for CIT funds.
- Streams: Development and Commercialization Program (DC), Technology Access Program (TAP), Sector Adoption
 Program (SAP), Talent Development Internships (TDI), and Future Ready Program (FR)
- Applicant: SMEs with less than 500 global full-time employees and registered operations in Ontario
- Partner: not required, but encouraged. Partners can be a private industry and/or public sector organizations
- Technology Development site: connection facilitated by OCI to support in the tech development
- Funding: project cost variable based on stream, upate \$1M6 (for SAP), with variable OCI contribution

Collaborating with regional partners Co-Funded Business Development



York University is partnering with Seneca Polytechnic and the Ontario Centre of Innovation (OCI) to boost the number of applied research opportunities for small- and medium-sized enterprises (SMEs) in the Greater Toronto Area and York Region, fostering greater connections between academics and industry.

October 17, 2023



New Partnership to Drive Innovation and Economic Growth in Ontario's Heartland

Through this collaboration, OCI, Trent University, Fleming College, ICPK, PKED, and Kawartha Lakes will establish a robust framework for fostering collaboration between academia and industry. By bridging the gap between theoretical knowledge and practical application, the partnership will enable businesses to access cutting-edge research and development resources.

April 17, 2024



Thank you

SANTIS



Identifying the Needs for Lab Space in Brampton

November 7, 2024

Study Goals

CBRE, in partnership with Santis Health, conducted a feasibility study to assess lab space demand for the life science sector in Brampton.

This feasibility study aims to identify the market demand for lab space, opportunities for partnerships, and the ideal composition of ecosystem players to create a thriving lab environment in Brampton that supports the growth of institutional players, collaboration with industry partners, and development of early-stage companies through a collaborative life sciences community.

This work will support the City of Brampton in:

- Providing insights to help start-up retention in Brampton and Ontario
- Acknowledging investments (past and future) in its Innovation District
- Help develop talent for growing firms
- Enhancing Brampton's role in Ontario Life Sciences Strategy growth

This study provides insights using **two** approaches:

- 1) Ecosystem Analysis
- 2) Real Estate Analysis

Study Approach: (1) Ecosystem Analysis



Semi-structured interviews:

1-hour semi-structured interviews.

Target groups: Government, Healthcare, Academia, Industry, Ecosystem Partners

- **27** Completed Interviews
- 1 Scheduling in Progress
- 2 Declined / Non-Responsive Interviews

We provided interviewees with overall questions in advance.

Overall interview questions:

- 1. What is the current state of lab space in Brampton?
- 2. Do you feel Brampton has the pieces/components for a thriving life sciences ecosystem?
- 3. What is the optimal location for new lab space in Brampton?
- 4. What would success look like for lab space in Brampton in 2-5 years?

Stakeholders Engaged

Government (n=3), Academia (n=4), **Industry** (n=11), **Ecosystem partners** (n=9)













F1RST GULF









Ministry of Economic Development, Job **Creation and Trade**































Study Approach: (2) Real Estate Analysis



Assessing the Demand

Determine the estimated **demand for laboratory space** and evaluate its **viability**.

- Market outreach through CBRE's proprietary "Tenants in the Market" list
- 2) Establish any demand from key local institutions and assess their needs



Location intelligence

To identify the ideal location for a thriving life science asset we analyzed the following criteria:

- 1) Demand and industry clusters
- 2) Transportation and accessibility
- 3) Proximity to skilled workforce and ideation
- 4) Partnership and collaboration opportunities

Our Research Generated 5 Key Insights

- 1. Many Stakeholders Possess a **General Awareness of Brampton's Advantages...BUT Knowledge** of Brampton's Specific Innovation Assets is Insufficient and Incomplete
- 2. Brampton Has the Critical Mix of "Anchor Institutions" Required to Support a Thriving Ecosystem and Strengthening Those Institutional Ties Will Be Critical to Future Growth
- 3. MedTech is Brampton's Area of Greatest Opportunity, while Start-Ups and SMEs Need Space AND Services
- 4. Phase II of Ontario's Life Sciences Strategy Comes at the Perfect Time
- 5. Brampton Has a Number of Logical Development Sites

1. Many Stakeholders Possess a General Awareness of Brampton's Advantages...BUT Knowledge of Brampton's Specific Innovation Assets is Insufficient and Incomplete

- **Brampton's location**, in the Toronto and Kitchener-Waterloo corridor, makes it attractive for medical innovation and talent access.
- Brampton offers more affordable real estate compared to neighbors.
- Close proximity to key partners enables engagement among healthcare professionals, academic institutions, and startups.
- Significant political will exists in Brampton to develop the life sciences sector.
- However, many stakeholders outside Brampton are uninformed about its strengths
 and unsure what differentiates the city in this sector.

Physical proximity is key in the context of how you sort of package it together and don't create an island unto yourself ...but leverage it

Brampton has political will, it is a less tangible piece but that is huge. It's really important because that would accelerate the development of this.

I was doing some Googling to try and understand if there was any sort of centralized repository of assets that are available but I could not find it

I know the medical school is coming but other than that, no.

2. Brampton Has the Critical Mix of "Anchor Institutions" Required to Support a Thriving **Ecosystem and Strengthening Those Institutional Ties Will Be Critical to Future Growth**



Partnerships with key stakeholders are essential for driving innovation and providing resources.



Medical and academic institutions can provide **resources**, such as Principal Investigators (PIs) and access to patient populations for preclinical studies.



Existing collaborations between startups, hospitals, and research institutions need better integration to provide access to lab spaces, product validation, and equipment.




The **need for streamlined processes** in place was emphasized for a successful collaboration in Brampton.




It would be great if the city would work collaboratively with the medical school to try to get funding from the FedDev regional development innovation program.



The medical school at TMU would be a great collaborative partner so that clinicians at the Med school would be on site as PIs to help access the patient population.



industry working together to achieve the impossible. To improve the health of the Brampton community through partnership, through collaboration, through an integrated approach, rather than everybody working in their own buildings with their own interests.



sense so that it's a bit less segregated

3. MedTech is Brampton's Area of Greatest Opportunity, while Start-Ups and SMEs Need Space AND Services



Brampton's medtech sector as its key strength in contrast with the biotech sector.

- There is currently no incubator or accelerator in the region for MedTech companies in areas such as quality management systems and regulatory needs.
- Biotech potential exists in oncology and mental health, supported by clinical research capabilities at William Osler.



Companies need space and services

- Early-stage MedTech companies in Brampton need clear processes and guidance to navigate commercialization.
- There is a lack of high-caliber mentors and regulatory advice.
- Startups struggle with funding for pre-clinical trials and pilot studies, making it difficult to enter new ecosystems effectively.

If Brampton decides to take a Medtech angle, they have to make sure it's complementary to whatever neighbors are doing. It is important to recognize what's their strength.

It might be that a coalition of those big medtech companies in Brampton gets formed. 66

So far we haven't had access to that caliber of mentor. We're looking for mentors that have been in the Medtech space for Class 2 devices.



The problem is to commercialize the technology, and commercialize an idea requires a very different skill Research groups are usually not good at that.

4. Phase II of Ontario's Life Sciences Strategy Comes at the Perfect Time

October 15, 2024: Announcement of Phase II of Life Sciences Strategy


- The Strategy focuses on promoting innovation, increasing investments, and advancing research to strengthen the province's position as a global leader in biomanufacturing and health sciences.
- The Strategy came with an **investment of \$146 million**. Some of the investments include:
- Up to \$46 million for the Ontario Biosciences Research Infrastructure Fund, to help boost research capacity at academic institutions and research hospitals.
- \$15 million for a new wet labs program to to make it easier for companies to access lab spaces.
- \$40 million from the Venture Ontario Fund to support venture capital for Ontario-based life sciences companies and biomanufacturers.
- Phase II promises a **new Health Innovation Pathway**, aimed to **streamline and simplify access** for health care organizations **to adopt groundbreaking technologies** with the priority to support Ontario-based innovations.


Real Estate Analysis - Assessing the Demand (I)

CBRE entered into the project with an expectation that the commercial demand it had been tracking throughout the GTHA would not justify a new lab development in Brampton. While that assumption wasn't proven to be wrong, we found something that proved to be far more critical.



118 active tenant requirements were surveyed on both their requirement status and asked the question of "what about Brampton"....unsurprisingly, results were mixed





The question that needed to be answered was whether or not the type of tenant demand that can support the underwriting of a new development existed. We found that the **viable institutional demand to support a development pro forma seems to exists from within Brampton**.....the question then is, how do we bring that together?

11

Real Estate Analysis - Assessing the Demand (II)

As mentioned, the project initially assumed that lab demand external to Brampton was the key factor to growing the sector, however, the City needs to **build the environment that not only attracts, but more importantly, fosters from within**...building this starts with the needs of the institutional anchors.



Early indications for the new school of medicine are that it will be focused on training clinical staff...**TMU needs to**have innovation planned into that facility



WOH needs to expand their research operations and if this can be done as part of a multi-tenanted facility, this would be a catalyst for innovation and collaboration



Both the location and space needs at BVZ are under consideration....if lab space was accessible, it would support start-up programming and provide a key component in the "suite of services"



Both **Algoma University and Sheridan College are expanding** science programming and could be a piece of the puzzle


Fostering a research partnership between academia and WOH will develop IP and new companies. Ensuring local **academic institutions develop talent** to support both healthcare research and large-local industry needs, will grow the existing employment base in Brampton.

Real Estate Analysis - Location Intelligence



After extensive stakeholder engagement, the sentiment was clear as to the corridor of innovation and opportunity for lab assets to support sector growth.

The proximity to universities, hospitals, and transit hubs (like GO Transit and the upcoming LRT) should play a key role in determining the location for a life sciences development



5. Brampton has a Number of Logical Development Sites

The clustering of research significantly impacts the proclivity for innovation and Brampton's foundational building blocks are the gravitational pull for future laboratory assets, making the Queen St corridor between downtown and Bramalea Civic Centre the key area of interest.



- The land on Queen Street directly in front of Peel Memorial Hospital and William Osler's research operations presents a great opportunity to have clinical services at your doorstep
- The TMU Medical School at Bramalea Civic Centre presents an opportunity for ideation to turn into IP if innovation is part of the programming

All three areas present strengths from an ecosystem building standpoint, but possess development hurdles that would need to be overcome for a project to advance.

What a Successful Outcome Looks Like

Two phases of development are required in a long term vision:

- Phase 1 should be a multi-tenanted facility which brings academic and healthcare research together and will give organic IP and early stage companies a place to germinate
- Phase 2 would be a larger facility where companies can expand when they've outgrown the phase 1 facility

An integrated partnership between institutional researchers and industry, working together to achieve the impossible. So, whether it be cures, drugs or medical devices, improve the health of the Brampton community through partnership, through collaboration, through an integrated approach, rather than everybody working in their own buildings with their own interests.

Phase 1- Stacking Plan



Preliminary Recommendations

Overview

Our recommendations are clustered into 3 broad buckets:

Funding

- 1) Work with supporters at Queen's Park to ensure that Phase II of Ontario's Life Sciences Strategy is flexible enough to accommodate the engineering and "dry labs" the Medtech sector needs not just the "wet labs" required by biopharma start-ups.
- 2) Identify existing and new opportunities to access funding from FedDev, based on the agency's previous investments in life sciences.

Partnerships and Programs

- 3) Develop an integrated marketing platform that highlights the Brampton ecosystem and clearly communicates how to access its key institutions, assets and initiatives.
- 4) Collaborate with Brampton's anchor institutions including WOH, TMU, Algoma, and Sheridan to foster the growth of early-stage companies by providing support with pre-clinical validation, clinical trials, access to animal facilities, mentorship, and regulatory consultation.

Infrastructure

- 5) Work with anchor institutions to determine their ability to integrate their future programming into a new facility that includes incubation space with the necessary physical traits and suite of services including partnerships for the start-up community to accelerate their commercialization process.
- 6) Encourage institutional labs and research requirements to come together in a collaborative, multitenant facility along the Queen Street Corridor. CBRE recommends the vacant land in front of Peel Memorial Hospital or downtown Brampton for any new build site, or, if possible, within the TMU Medical School if there is excess space that has yet to be programmed.

Confidential & Proprietary | © 2024 CBRE, Inc.



Thank you.



MedTech Task Force

All meetings commence at 4:00 p.m. and will be hybrid (virtual and inperson) in the Council Chambers – 4 the Floor, City Hall (Location and format of the meeting will be noted on the agenda)

Meeting Dates		
April 24, 2025		
November 13, 2025		

Members: If you are unable to attend a meeting, please contact

Tammi Jackson, Legislative Coordinator, via email at tammi.jackson@brampton.ca at your earliest possible

convenience.